Enhanced recovery after surgery protocol and postoperative opioid prescribing for cesarean delivery: an interrupted time series analysis

E. M. Langnas 1*, Z. A. Matthay 2, A. Lin 3, M. W. Harbell 1,7, R. Croci 8, R. Rodriguez-Monguio 4,5,6 and C. L. Chen 1,6

Abstract

Introduction: Enhanced recovery after surgery (ERAS) pathways have emerged as a promising strategy to reduce postoperative opioid use and decrease the risk of developing new persistent opioid use in surgical patients. However, the association between ERAS implementation and discharge opioid prescribing practices is unclear.

Study design: We conducted a retrospective observational quasi-experimental study of opioid-naïve patients aged 18+ undergoing cesarean delivery between February 2015 and December 2019 at a large academic center. An interrupted time series analysis (ITSA) was used to model the changes in pain medication prescribing associated with the implementation of ERAS to account for pre-existing temporal trends.

Results: Among the 1473 patients (out of 2249 total) who underwent cesarean delivery after ERAS implementation, 80.72% received a discharge opioid prescription vs. 95.36% at baseline. Pre-ERAS daily oral morphine equivalents (OME) on the discharge prescription decreased by 0.48 OME each month (p<0.01). There was a level shift of 35 more OME prescribed (p<0.01), followed by a monthly decrease of 1.4 OMEs per month after ERAS implementation (p<0.01). Among those who received a prescription, 61.35% received a total daily dose greater than 90 OME compared to 11.35% pre-implementation (p<0.01), while prescriptions with a total daily dose less than 50 OME decreased from 79.86 to 25.85% after ERAS implementation (p<0.01).

Conclusion: Although ERAS implementation reduced the overall proportion of patients receiving a discharge opioid prescription after cesarean delivery, for the subset of patients receiving an opioid prescription, ERAS implementation may have inadvertently increased the prescribing of daily doses greater than 90 OME. This finding highlights the importance of early and continued evaluation after new policies are implemented.

Keywords: Opioids, Cesarean delivery, Multimodal analgesia, Oral morphine equivalents, Postoperative pain

*Correspondence: Erica.Langnas@ucsf.edu

1Department of Anesthesia and Perioperative Care, University of California, San Francisco, 513 Parnassus Ave, S455, San Francisco, CA 94143, USA

Full list of author information is available at the end of the article
Introduction

In the USA, opioids are often over-prescribed to patients after surgical procedures, which results in excess and unused opioids (Berterame et al. 2016; Baker et al. 2016; Wunsch et al. 2016; Bicket et al. 2017; Brummett et al. 2019; Howard et al. 2019). Excess opioids prescribed at discharge are a potential source for overdose, misuse, diversion, and new persistent opioid use among surgical patients (Berterame et al. 2016; Dowell et al. 2013; Brummett et al. 2017). Specialty guidelines and consensus statements have emerged to address the need for providing adequate pain control while mitigating the risk of opioid-related adverse effects (American Society of Anesthesiologists Task Force on Acute Pain Management 2012; Levy et al. 2021).

Cesarean delivery is the most common inpatient surgical procedure performed in the USA with approximately 1.3 million cesarean deliveries performed annually (Martin et al. 2018). Almost all women undergoing cesarean delivery are exposed to opioids during their hospitalization, and 85% of women fill their first opioid prescription upon hospital discharge (Bateman et al. 2017). Between 0.4 and 2.2% of women who received an opioid prescription after cesarean delivery become persistent opioid users (Bateman et al. 2017; Peahl et al. 2019). Furthermore, 83% of women undergoing cesarean delivery reported having leftover prescription opioids, which may increase the risk of misuse or diversion (Barrels et al. 2016).

Enhanced Recovery After Surgery (ERAS) pathways have emerged as a promising strategy to reduce opioid consumption after surgery (Wick et al. 2017). ERAS pathways utilize a standardized multimodal analgesic regimen that includes non-opioid analgesics to minimize perioperative opioid use. ERAS has been effective in reducing inpatient opioid consumption and discharge opioid prescriptions in a variety of surgical procedures (Page et al. 2016; Talboys et al. 2016; Sarin et al. 2016; Chapman et al. 2016; Liu et al. 2020; Hederson et al. 2019). However, it is unclear how implementation of standardized protocols impacts provider prescribing habits. Prior studies on ERAS implementation that utilize pre- and post-cohort analyses do not necessarily account for longitudinal temporal trends in the data, since all of the data is essentially clustered and analyzed within the two groups.

To examine the association between the ERAS implementation for cesarean delivery and opioid prescribing patterns over time, we conducted an interrupted time series analysis at a large academic medical center using electronic medical record (EMR) data. Our secondary aim was to evaluate trends in pain medication administration 24 h prior to discharge, as well as the trends in opioid refills within 90 days of discharge.

Methods

Study design and data source

We conducted a single-center, retrospective, observational quasi-experimental study of opioid-naïve patients aged 18+ undergoing cesarean delivery from February 2015 through December 2019 at the University of California San Francisco Medical Center (UCSF). This study was approved by the UCSF IRB, which waived patient consent for acquisition of data (IRB# 18-26728). Data was obtained by retrospective database queries of the UCSF electronic medical record (Epic Systems, Verona, WI).

After extraction from an electronic data warehouse, the data were validated for accuracy with iterative chart auditing. To ensure accurate and complete data extraction, data reports were evaluated to identify inconsistencies, missingness, extreme values, and invalid codes. Discrepancy management included reviewing discrepancies, investigating the reason, and resolving them. The data extracted had no missingness. After a proper quality check and assurance, the final dataset was locked so that the dataset could not be modified and only the final clean dataset was used for analysis.

Study cohort

Our study included opioid-naïve patients aged 18 years and older who underwent elective or non-elective cesarean delivery and who were discharged to either home, a skilled nursing facility, or a rehabilitation facility. We defined opioid-naïve as any patient without an active opioid prescription documented in their electronic medical record (EMR) starting 6 months prior to hospital admission.

Enhanced recovery after surgery

After multidisciplinary involvement from obstetrics, anesthesiology, pediatrics and lactation, an ERAS protocol for cesarean delivery was implemented for elective cesarean delivery starting on February 1, 2017. Prior to implementation, anesthesiology and obstetric attending physicians, residents, nurses, and midwives underwent training and education of the ERAS pathway, and order sets were created in the EMR to facilitate compliance with the ERAS pathway. The institutional ERAS protocol for inpatient pain management for cesarean delivery recommended oral acetaminophen 1000 mg every 8 h, intravenous ketorolac 30 mg every 8 h for 3 doses followed by oral ibuprofen 600 mg every 6 h, and oral oxycodone 5–10 mg as needed for moderate pain. Patients could receive morphine 0.2–0.6 mg intravenously (IV) as needed for severe pain, but only after evaluation by an anesthesia provider. The default order set for discharge medications
included acetaminophen 1000 mg every 8 h, ibuprofen 600 mg every 6 h, and oxycodone 5 to 10 mg every 4 h as needed for a maximum of twenty pills without any refills.

**Opioid dose calculation**

To compare pre- and post-discharge opioid administration, we converted all IV, oral, regional, and neuraxial opioid consumed in the 24 h leading up to hospital discharge into oral morphine equivalents (OME) using the 2018 UCSF Pain Management Committee’s opioid equivalence equation (University of California San Francisco, Pain Management Committee’s 2018). The opioid dosage on the discharge opioid prescription was also converted into OMEs using the same opioid conversion equation. The daily dose on the discharge opioid prescription was defined as the maximum allowable dose in a 24 h period according to the written prescription.

**Definition of high-risk prescription**

The risk of opioid-related adverse events is associated with the maximum daily OME prescribed (Bohnert et al. 2011; Brat Gabriel et al. 2018). Consistent with CDC recommendations, we defined a high-risk prescription as a discharge opioid prescription exceeding 90 OME per day, which has been associated with an increased risk of opioid-related adverse effects, including overdose death (Dowell et al. 2016).

**Covariates**

We assessed other variables that may be associated with the opioid discharge prescription, including patient demographic characteristics, history of substance use disorder diagnosis, depression or anxiety diagnosis, discharge service, and hospital length of stay (LOS).

**Statistical analysis**

Data were summarized using mean and standard deviations for continuous and normally distributed variables, median and interquartile ranges for non-normally distributed variables, and as percentages for binary variables. Chi-squared tests were used to compare patient characteristics pre- and post-ERAS implementation.

An interrupted time series with segmented regression analysis (ITSA) was used to model the changes in pain medication prescribing practices associated with the implementation of ERAS. All ITSAs were performed using the ordinary least squares method with Newey-West standard errors (Linden 2015). A Cumby-Huizinga test was used to assess temporal autocorrelation, and standard error adjustments were incorporated for up to a 12-month lag in our models. As a sensitivity analysis, we examined whether patient characteristics (age and length of stay) or prescribing provider type (trainee or clinical nurse midwife) affected the models when included as covariates (Table 3 in Appendix). None of these significantly altered the association of ERAS with the pain medication outcome variables and therefore were not included in the final models. All data analyses were performed in Stata (Version 15, Stata Corps).

**Results**

A total of 2249 opioid-naïve patients underwent cesarean delivery during the study period. We found significant differences in opioid use and prescribing practices pre- and post-ERAS implementation (Table 1). Post-ERAS, 49.76% of patients did not require opioids in the 24 h prior to discharge, compared to 21.01% pre-ERAS (p<0.01). In addition, 80.72% of patients were discharged with an opioid prescription post-ERAS implementation compared to 95.35% of patients pre-ERAS implementation (p<0.01). Among those who received a prescription, 96.55% of post-ERAS opioid type was oxycodone, compared to 17.03% pre-ERAS (p<0.01). Post-ERAS 61.35% received a total daily dose greater than 90 OME compared to 11.35% pre-ERAS (p<0.01), while prescriptions with a total daily dose less than 50 OME decreased from 79.86 to 25.85% after ERAS implementation (p<0.01). In addition, post-ERAS, we found a reduction in the mean days’ supply on the discharge prescription (5.48 days vs 2.23 days, p<0.01). There was no significant change in postoperative length of stay post-ERAS (Figure 4 in Appendix).

An interrupted time series analysis was used to evaluate the association of ERAS on pain medication consumption in the 24 h prior to discharge (Fig. 1, Table 2). There was a statistically significant increase (77%) in acetaminophen consumption 24 h prior to discharge immediately following ERAS implementation (p<0.01) (Fig. 1a). In contrast, there was no significant change in the consumption of NSAIDs prior to discharge (Fig. 1b).

Pre-ERAS opioid consumption in the 24 h prior to discharge showed a month-to-month reduction of 0.48 OME (p<0.01) (Fig. 1c). There was a post-intervention level change of 2.7 fewer OMEs prescribed which was approaching significance (p=0.06), followed by a post-intervention monthly reduction of 0.07 OMEs (p<0.01) (Fig. 1c).

Pre-ERAS daily OMEs on the opioid discharge prescription showed a month-to-month reduction of 0.48 OME (p<0.01) (Fig. 2a). There was a post-intervention level change of 35 more OMEs prescribed (p<0.01), followed by a post-intervention monthly reduction of 1.4 fewer OMEs per month (p<0.01) (Fig. 2a). Pre-ERAS total OME on the discharge prescription decreased by 2.26 OME per month (p<0.01), followed by a post-intervention level change of 51.5 fewer OMEs prescribed at hospital discharge (p<0.05) (Fig. 2b). Post-ERAS total
OME on the discharge prescription continued to decrease by 3.78 OME per month ($p<0.01$) (Fig. 2b).

Pre-ERAS, the proportion of patients receiving opioid refills decreased by 0.03% per month, followed by a post-intervention level change of 4.96% ($p=0.04$) (Fig. 3, Table 2). Post-ERAS opioid prescription refills followed a similar trend with a reduction of 0.02% per month that was not statistically significant compared to pre-intervention ($p=0.85$).

When comparing patients who received a discharge opioid prescription with those who did not, we found no significant differences in patient age, race, or length of stay (Tables 4 and 5 in Appendix). Pre-ERAS, patients who did not have an opioid prescribed at discharge were more likely to be opioid free the 24 h prior to discharge compared to patients who did receive a discharge opioid prescription (88.9% vs. 17.7%, $p<0.01$) (Table 4 in Appendix). Similarly, post-ERAS patients who did not have an opioid prescribed at discharge were more likely to be opioid free in the 24 h prior to discharge compared to patients who did receive a discharge opioid prescription (91.2% vs. 39.8%, $p<0.01$) (Table 5 in Appendix).

**Discussion**

Consistent with prior studies examining the effects of ERAS pathways, our study found a variety of benefits associated with the implementation of pain management guidelines at our institution for patients undergoing cesarean delivery (Shinnick et al. 2020). These benefits included an increase in the adoption of inpatient multimodal analgesia and a reduction in inpatient opioid consumption. In addition, there was a reduction in the proportion of patients receiving a discharge opioid prescription and a reduction in opioid refills in the first 90 days after discharge.

Using ITSA, we were able to identify nuanced temporal prescribing changes that have not been captured in prior ERAS cesarean cohort analyses. Our institution’s ERAS protocol, which is intended to reduce opioid over-prescribing, was paradoxically associated with a significant increase in the strength (daily OMEs) of the discharge opioid prescriptions. This finding suggests that implementation of the ERAS protocol may have inadvertently increased the daily dose of opioid prescribed to
patients who received an opioid prescription. The largest increase in daily OMEs on the discharge prescription occurred immediately after the implementation phase and steadily decreased over time. This is concerning given that increases in daily OMEs on discharge prescriptions are associated with increases in misuse or overdose events (Dowell et al. 2016). Furthermore, the post-ERAS cohort had a higher rate of discharge prescriptions exceeding 90 daily OMEs. This increase in high-risk prescriptions was accompanied by a decrease in total OMEs on the discharge prescription after ERAS implementation. Our results suggest that the ERAS pathway was associated with a higher daily OME written on the discharge prescription, but for a shorter duration. In addition, we found a significant change in opioid type to oxycodone. These findings directly reflect the ERAS protocol, which limited prescriptions to 20 pills and defined the maximum dose of 10 mg of oxycodone every 4 h, which translates to 90 daily OMEs. Based on our results, we believe that when prescribers are provided a dosing range to choose from, there is a risk of defaulting to the maximum dose recommended, and this finding should be considered when designing pain medication order sets for implementation in the EHR.

The potential effects that opioid dose or duration limits have on physician opioid prescribing behavior remains variable (Agarwal et al. 2019a; Echeverria-Villalobos et al. 2020). A multitude of factors affect prescribing behaviors, including diagnostic skills, clinical judgement, drug knowledge, financial incentives, and

| Table 2 Interrupted time series analysis examining pain medication utilization pre- and post-intervention |
|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
|                                                                                                        | Coefficient | 95% CI low | 95% CI high | P value |
| Proportion prescribed tylenol 24 h prior to discharge                                                                 |
| Pre-ERAS trend (Jan 2015–Sep 2016)                                                                        | 0.01        | 0.01       | 0.01         | <0.01   |
| Level shift after ERAS implementation                                                                      | 0.77        | 0.75       | 0.78         | <0.01   |
| Trend shift after ERAS implementation                                                                      | −0.01       | −0.01      | −0.01        | <0.01   |
| Post-ERAS trend (Feb 2017–Dec 2019)                                                                        | 0.00        | 0.00       | 0.00         | <0.01   |
| Proportion prescribed NSAIDs 24 h prior to discharge                                                                 |
| Pre-ERAS trend (Jan 2015–Sep 2016)                                                                        | 0.01        | 0.00       | 0.03         | 0.12    |
| Level shift after ERAS implementation                                                                      | −0.07       | −0.20      | 0.05         | 0.25    |
| Trend shift after ERAS implementation                                                                      | −0.01       | −0.02      | 0.01         | 0.38    |
| Post-ERAS trend (Feb 2017–Dec 2019)                                                                        | 0.00        | 0.00       | 0.01         | <0.01   |
| Mean OME administered in 24 h prior to discharge                                                                 |
| Pre-ERAS trend (Jan 2015–Sep 2016)                                                                        | −0.45       | −0.60      | −0.29        | <0.01   |
| Level shift after ERAS implementation                                                                      | −2.27       | −4.64      | 0.10         | 0.06    |
| Trend shift after ERAS implementation                                                                      | 0.37        | 0.22       | 0.53         | <0.01   |
| Post-ERAS trend (Feb 2017–Dec 2019)                                                                        | −0.07       | −0.13      | −0.02        | 0.01    |
| Total OME prescribed at discharge                                                                            |
| Pre-ERAS trend (Jan 2015–Sep 2016)                                                                        | −2.26       | −3.54      | −0.98        | <0.01   |
| Level shift after ERAS implementation                                                                      | −51.50      | −95.97     | −7.04        | 0.02    |
| Trend shift after ERAS implementation                                                                      | −1.52       | −3.34      | 0.29         | 0.10    |
| Post-ERAS trend (Feb 2017–Dec 2019)                                                                        | −3.78       | −5.59      | −1.97        | <0.01   |
| Daily OME prescribed at discharge                                                                             |
| Pre-ERAS trend (Jan 2015–Sep 2016)                                                                        | −0.48       | −0.75      | −0.22        | <0.01   |
| Level shift after ERAS implementation                                                                      | 34.83       | 29.13      | 40.53        | <0.01   |
| Trend shift after ERAS implementation                                                                      | −0.89       | −1.22      | −0.57        | <0.01   |
| Post-ERAS trend (Feb 2017–Dec 2019)                                                                        | −1.38       | −1.62      | −1.13        | <0.01   |
| Proportion prescribed opioid refill within 90 days after discharge                                             |
| Pre-ERAS trend (Jan 2015–Sep 2016)                                                                        | −0.03%      | −0.25%     | 0.18%        | 0.77    |
| Level shift after ERAS implementation                                                                      | −4.96%      | −9.68%     | −0.24%       | 0.04    |
| Trend shift after ERAS implementation                                                                      | 0.01%       | −0.23%     | 0.26%        | 0.91    |
| Post-ERAS trend (Feb 2017–Dec 2019)                                                                        | −0.02%      | −0.19%     | 0.15%        | 0.85    |

OME oral morphine equivalents, ERAS enhanced recovery after surgery, NSAIDs non-steroidal anti-inflammatory drugs, CI confidence interval
Fig. 1 (See legend on next page.)
Fig. 1 Changes in medications consumed 24 h prior to discharge, 2015–2019. Data are presented in monthly intervals on the x-axis. Vertical dashed lines represent the implementation phase. DC = discharge; OME = oral morphine equivalent; ERAS = Enhanced recovery after surgery; NSAID = non-steroidal anti-inflammatory.

a Proportion of patients receiving acetaminophen in the 24 h prior to discharge. Post-ERAS associated with a level increase of 77% (p<0.01).

b Proportion of patients receiving NSAID in the 24 h prior to discharge. No significant change was noted post-ERAS.

c Mean oral morphine equivalents administered 24 h prior to discharge. Post-ERAS level change of 2.7 fewer OME (p=0.06).

Fig. 2 Change in total and daily oral morphine equivalents on the discharge opioid prescription, 2015–2019. Data are presented in monthly intervals on the x-axis and oral morphine equivalents on the y-axis. Vertical dashed lines represent the implementation phase. DC = discharge; OME = oral morphine equivalent; ERAS = Enhanced recovery after surgery.

a Changes in mean daily OME on the discharge prescription. Post-ERAS implementation associated with a level change of 35 more daily OME prescribed (p<0.01).

b Changes in total OME on discharge prescription. Post-ERAS implementation associated with a level change of 51.5 fewer OME prescribed (p<0.05).
motivation to remain up to date on medical practices, which are variable among practitioners (Stern and Trajtenberg 1998). It is possible that our ERAS protocol nudged physicians into prescribing in the higher range of the suggested discharge opioid prescription resulting in a higher daily OME in the early post-ERAS time period. Drivers for this behavior were not explored in our study, but may include concerns regarding patient need for refills and ensuring patient satisfaction. It is possible that prescribers chose to prescribe higher opioid doses to ensure adequate pain control after ERAS guidelines recommended an upper limit on the number of pills prescribed.

Our findings highlight important and modifiable consequences with ERAS implementation. First, there is a need for data collection and evaluation at early phases of policy implementation to identify the effects of protocolization of prescribing behaviors. It may be reasonable to deploy small pilot studies to help identify and mitigate any unintended consequences prior to rolling out new policies on larger cohorts. Second, protocolization of care may prove beneficial for inpatient pain management, but might be problematic for discharge opioid prescriptions. Other studies have emphasized the benefits of individualized or patient-tailored prescribing practices to reducing excessive opioid prescribing instead of relying on a one-size fits all approach (Hill et al. 2018; Agarwal et al. 2019b). Consistent with the recommendation by Levy et al. in their international consensus statement on preventing opioid-related harm in adult surgical patients, a patient-centered approach should be utilized when determining the discharge opioid prescription to reduce over prescribing after surgery (Levy et al. 2021). Initiatives to develop and modify ERAS protocols should balance the goals of safe opioid prescribing in surgical patients and avoidance of inadvertent harm arising from these policies while ensuring that individual patients’ pain management needs are adequately managed during the inpatient stay as well as post-discharge.

Limitations
Our study was conducted during a time of increasing evidence of harm associated with unsafe opioid prescribing practices along with the introduction of national- and state-level opioid prescribing initiatives, which may have contributed to the changes in opioid prescribing practices we found. Nationally, the CDC published guidelines for prescribing opioids for chronic pain (Dowell et al. 2016). However, these guidelines were intended for chronic pain patients, not for acute postoperative opioid naïve patients. The state of California, where our study is located, did not pass any state-specific legislation to limit opioid prescriptions during the study period. However, California did update its prescription drug monitoring programs (PDMP) policy in July 2016 to require mandatory registration of opioid prescribers,
when previously this was voluntary. Regardless, mandatory PDMP registration has not been shown to significantly reduce opioid prescriptions for surgical patients (Stucke et al. 2018).

In addition, our data is from a single large, tertiary, academic medical center and our observations may not be generalizable to patients undergoing cesarean delivery or other surgical procedures at non-academic centers or in other regions of the country. The retrospective observational study design using electronic health records limits our ability to assert a direct causal relationship between the explanatory factors in our model and opioid prescribing patterns. It is possible that factors that were unaccounted for in our model may contribute to the observed findings if these occurred at the same time as ERAS implementation. It is also important to note that ITSA models assume a linear relationship to estimate the change in the outcomes over time during the pre- and post-ERAS implementation phases, but more nuanced relationships may exist. In addition, our data was unable to account for inpatient administration of acetaminophen that was in combination with an opioid (i.e., hydrocodone-acetaminophen, oxycodone-acetaminophen). As a result, pre-ERAS acetaminophen administration prior to discharge may be underestimated. Finally, our data captured discharge prescriptions written for patients but does not capture if the prescription was filled nor how much opioid was actually taken by the patient. Therefore, patients may not have been exposed to the doses of opioids prescribed at hospital discharge. Despite these limitations, our study highlights the importance of longitudinal evaluation of opioid prescribing practices after new guidelines are implemented to understand whether they are having the intended effect and to mitigate against perpetuating high-risk opioid prescribing practices.

**Conclusions**

In this study, we identified unintended consequences of provider opioid prescribing patterns in the immediate post-ERAS implementation period for patients undergoing cesarean delivery at a large tertiary academic medical center. While ERAS implementation led to an increase in multimodal analgesia and opioid-free pain control in the last 24 h prior to discharge, we also found a significant increase in the daily OME written on the discharge opioid prescription. These findings highlight the importance of early and continued evaluation after the implementation of new policies that are intended to reduce the risk of opioid exposure in selected patients.

### Table 3

| Coefficient | 95% CI low | 95% CI high | P value |
|-------------|-----------|-------------|---------|
| Pre-ERAS trend (Jan 2015–Sep 2016) | − 0.53 | − 0.75 | − 0.32 | <0.01 |
| Level Shift after ERAS implementation | 34.93 | 29.63 | 40.22 | <0.01 |
| Trend Shift after ERAS implementation | − 0.77 | − 1.11 | − 0.43 | <0.01 |
| Provider type | 3.55 | − 12.17 | 19.28 | 0.65 |
| Age | 1.57 | − 0.69 | 3.82 | 0.17 |
| Postoperative length of stay | 5.76 | − 3.09 | 14.62 | 0.20 |

### Table 4

| Opioid prescribed (n=740) | No opioid prescribed (n=36) | P value |
|---------------------------|---------------------------|---------|
| Age, mean (SD) | 34.06 (5.15) | 33.83 (5.54) | 0.79 |
| Race, n (%) | | | |
| White or Caucasian | 328 (44.32) | 19 (52.78) | 0.15 |
| Asian | 169 (22.84) | 11 (30.56) | |
| Black or African American | 48 (6.49) | 1 (2.78) | |
| Native Hawaiian or Other Pacific Islander | 16 (21.62) | 0 (0) | |
| American Indian or Alaska Native | 4 (0.54) | 0 (0) | |
| Unknown | 175 (23.65) | 5 (13.89) | |
| Opioid-free 24 h pre-discharge, n (%) | 131 (17.70) | 32 (88.89) | <0.01 |
| Length of stay in days, mean (SD) | 3.97 (1.34) | 3.82 (0.72) | 0.51 |
Change in postoperative length of stay, 2015–2019. Data are presented in monthly intervals on the x-axis and days on the y-axis. Vertical dashed lines represent the implementation phase. LOS= length of stay. Post-ERAS implementation was associated with a level change of −0.03 days and slope change of −0.02 days (p=0.76 and p=0.06, respectively).

Table 5 Clinical and demographic characteristics of post-ERAS cohort by receipt of opioid prescription at discharge

|                               | Opioid prescribed (n=1188) | No opioid prescribed (n= 285) | P value |
|--------------------------------|----------------------------|-------------------------------|---------|
| Age, mean (SD)                 | 35.56 (5.488)              | 34.92 (5.38)                  | 0.08    |
| Race, n (%)                    |                            |                               | 0.24    |
| White or Caucasian             | 549 (46.21)                | 128 (44.91)                   |         |
| Asian                          | 256 (21.55)                | 79 (27.72)                    |         |
| Black or African American      | 73 (6.14)                  | 14 (4.91)                     |         |
| Native Hawaiian or Other Pacific Islander | 17 (1.43) | 2 (0.7)                      |         |
| American Indian or Alaska Native | 8 (0.67)     | 0 (0.0)                      |         |
| Unknown                        | 285 (23.99)                | 62 (21.75)                    |         |
| Opioid-free 24 h pre-discharge, n (%) | 473 (39.81%)  | 260 (91.22%)                 | <0.01   |
| Length of stay in days, mean (SD) | 3.65 (1.50)              | 3.63 (0.99)                   | 0.83    |
Abbreviations
ERAS: Enhanced Recovery After Surgery; OME: Oral morphine equivalent; NSAID: Non-steroidal anti-inflammatory drug

Acknowledgements
We thank the editor and reviewers for their insightful suggestions.

Authors’ contributions
Study conception and design were done by LA, LEM, MZA, HMW, and RMR. Acquisition of data were done by LEM, MZA, CR, and MZA. Analysis and interpretation of data were done by LA, LEM, MZA, CR, HMW, CCL, and RMR. Drafting of the manuscript was done by LA, LEM, CCL, RMR, and MZA. Critical revision was done by LEM, CCL, HMW, RMR, and MZA. The authors read and approved the final manuscript.

Funding
None to disclose.

Availability of data and materials
Raw large-scale electronic medical record data were generated at our institution.

Declarations
Ethics approval and consent to participate
This study was approved by the UCFS IRB, which waived patient consent for acquisition of data (IRB# 18-26728).

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Anesthesia and Perioperative Care, University of California, San Francisco, San Francisco, CA 94143, USA.
2Department of Surgery, University of California, San Francisco, San Francisco, USA.
3UCSF School of Medicine, University of California, San Francisco, San Francisco, USA.
4Department of Clinical Pharmacy, University of California, San Francisco, San Francisco, USA.
5Medication Outcomes Center, University of California, San Francisco, San Francisco, USA.
6Philip R. Lee Institute for Health Policy Studies at the University of California, San Francisco, San Francisco, USA.
7Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Phoenix, AZ 85054, USA.
8UCSF Health Informatics, University of California, San Francisco, San Francisco, USA.

Received: 26 April 2021 Accepted: 18 July 2021
Published online: 15 November 2021

References
Agarwal S, Bryan JD, Hu HM, Lee JS, Chua KP, Haffajee RL, et al. Association of state opioid duration limits with postoperative opioid prescribing. JAMA Netw Open. 2019a;2(12):e1918361. https://doi.org/10.1001/jamanetworkopen.2019.18361.
Agarwal S, Bryan JD, Hu HM, Lee JS, Chua KP, Haffajee RL, et al. Association of state opioid duration limits with postoperative opioid prescribing. JAMA Netw Open. 2019b;2(12):e1918361. https://doi.org/10.1001/jamanetworkopen.2019.18361.
Baker JA, Avorn J, Levine R, Bateman BT. Opioid prescribing after surgical extraction of teeth in Medicaid patients, 2000-2010. JAMA. 2016;315(15):1633–4. https://doi.org/10.1001/jama.2015.19058.
Bartels K, Mayes LM, Dingmann C, Bullard KJ, Hopfer CJ, Binswanger IA. Opioid use and storage patterns by patients after hospital discharge following surgery. PLoS ONE. 2016;11(11):e0147972. Accessed Mar 17, 2020. https://doi.org/10.1371/journal.pone.0147972.
Bateman BT, Cole NM, Maeda A, Burns SM, Houle TT, Huybrechts KF, et al. Patterns of opioid prescription and use after cesarean delivery. Obstet Gynecol. 2017;130(1):29–35. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5600205/.
Beterame S, Ethal J, Thomas J, Fellenor S, Vosse B, Clare P, et al. Use of and barriers to access to opioid analgesics: a worldwide, regional, and national study. Lancet. 2016;387(10028):1644–56. https://doi.org/10.1016/S0140-6736(16)30106-6.
Bickert MC, Long JJ, Pronovost PJ, Alexander GC, Wu CL. Prescription opioid analgesics commonly unused after surgery: a systematic review. JAMA Surg. 2017;152(11):1066–71. https://doi.org/10.1001/jamasurg.2017.0831.
Bohnet AS, Valenstein M, Bair MJ, Ganoczy D, McCarthy J, Ilgen MA, et al. Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA. 2011;305(13):1315–21. https://doi.org/10.1001/jama.2011.311370.PMID:21467284.
Brat GA, et al. 2018. Post-surgical prescriptions for opioid naïve patients and association with overdose and misuse: retrospective cohort study. BMJ. p. j5790. Available at: https://doi.org/10.1136/bmj.j5790.
Brummett CM, Steiger R, Englesbe MJ, et al. Effect of an activated charcoal bag on disposal of unused opioids after an outpatient surgical procedure: a randomized clinical trial. JAMA Surg. 2019;154(6):558–61. https://doi.org/10.1001/jamasurg.2019.0155.
Brummett CM, Waljee JF, Goelging J, Moser S, Lin P, Englesbe MJ, et al. New persistent opioid use after minor and major surgical procedures in US adults. JAMA Surg. 2017;152(6):e170504. https://doi.org/10.1001/jamasurg.2017.0504.
Chapman JS, Roddy E, Ueda S, Brooks R, Chen LL, Chen LM. Enhanced recovery pathways for improving outcomes after minimally invasive gynecologic oncology surgery. Obstet Gynecol. 2016;128(1):138–44. https://doi.org/10.1097/AOG.0000000000001466. Accessed Feb 17, 2020.
Dowell D, Haegerich TM, Chou R. CDC Guideline for prescribing opioids for chronic pain — United States, 2016. MMWR Recomm Rep. 2016;1. https://doi.org/10.15585/mmwr.mm6510e1externalicon.
Dowell D, Kunins HV, Farley TA. Opioid analgesics—risks drugs, not risky patients. JAMA. 2013;309(21):2219–20. https://doi.org/10.1001/jama.2013.794.
Echeverria Villabobos M, Stoica E, Nokes AB, Sodichini AB, Fierda-Diaz J, Urrie AA, Weaver T, et al. Enhanced Recovery After Surgery (ERAS): a perspective review of postoperative pain management under ERAS pathways and its role on opioid crisis in the United States. Clin J Pain. 2020;36(3):219–26. https://doi.org/10.1097/AJP.0000000000000792.PMID:31868759.
Hederson M, Lee D, Hunt E, Lee K, Xu F, Mustille A, et al. Enhanced recovery after surgery to change process measures and reduce opioid use after cesarean delivery: a quality improvement initiative. Obstet Gynecol. 2019;134(4):511–9. Accessed Feb 17, 2020. https://doi.org/10.1097/AOG.0000000000002406.
Hill MV, Stucke RS, Billmeier SE, Kelly JL, Barth JR. Guideline for the reduction of opioid use in surgical procedures. World Neurosurg. 2020. Accessed Feb 17, 2020;136:e542–543. https://doi.org/10.1016/j.wneu.2020.01.067.
Howard R, Fry B, Gunaseelan V, Lee J, Waljee J, Brummett C, et al. Association of opioid prescribing with opioid consumption after surgery in Michigan. JAMA Surg. 2019;154(1):e184234. https://doi.org/10.1001/jamasurg.2018.4234.
Levy N, Quinlan J, El-Boghdady K, Fawcett WJ, Agarwal V, Bastable RB, et al. Use of and barriers to effect of an activated charcoal bag on disposal of unused opioids after an outpatient surgical procedure: a randomized clinical trial. JAMA Surg. 2017;152(6):e170504. https://doi.org/10.1001/jamasurg.2017.0504.
Li Y, de Wolff-Piotrowski S, Hanley JA, Hamilton BE, Ostermann AJM, Driscoll AK, Drape P. Births: final data for 2017. Natl Vital Stat Rep. 2018;67(8):1. https://doi.org/10.17322/mmrwr.rr6501e1external.icon.
Linden A. Conducting interrupted time-series analysis for single and multiple group comparisons. The Stata Journal. 2015;15(2):480–500. https://doi.org/10.1177/1536867X1501500208.
Liu B, Liu S, Wang Y, Zhao L, Zheng T, Chen L, et al. Enhanced Recovery After Intrapelvic Tumor Surgery: A Single-Institutional Randomized Controlled Study. World Neurosurg. 2020. Accessed Feb 17, 2020;136:e542–52. https://doi.org/10.1016/j.wneu.2020.01.067.
Martin A, Hamilton BE, Osterman AJM, Driscoll AK, Drake P. Births: final data for 2017. Natl Vital Stat Rep. 2018;67(8):1–50.
Page AJ, Gani F, Crowley KT, Lee KKH, Grant MC, Zawadsky TL, et al. Patient outcomes and provider perceptions following implementation of a standardized perioperative care pathway for open liver resection. Br J Surg. 2016;103(5):564–71. https://doi.org/10.1002/bjs.10087. Accessed Feb 17, 2020.
Pain Management Committee’s 2018 Opioid Equivalent Algorithm. University of California, San Francisco, California. http://links.lww.com/ALN/B738.
Peah AF, Dalton VK, Montgomery JR, Lai YL, Hu HM, Waljee JF. Rates of new persistent opioid use after vaginal or cesarean birth among US women. JAMA Netw Open. 2019;2(7):e197863. Accessed Mar 17, 2020. https://doi.org/10.1001/jamanetworkopen.2019.7863.
Practice Guidelines for Acute Pain Management in the Perioperative Setting. Anesthesiology. 2012;116(2):248–73. https://doi.org/10.1097/aln.0b013e3182c1030

Sarin A, Litonius ES, Naidu R, Yost CS, Varma MG, Chen LL. Successful implementation of an enhanced recovery after surgery program shortens length of stay and improves postoperative pain, and bowel and bladder function after colorectal surgery. BMC Anesthesiol. 2016;16(1):55. https://doi.org/10.1186/s12871-016-0223-0. Accessed Feb 17 2020.

Shinnick JK, Ruhotina M, Has P, Kelly BJ, Brousseau EC, et al. Enhanced recovery after surgery for cesarean delivery decreases length of hospital stay and opioid consumption: a quality improvement initiative. American Journal of Perinatology. 2020. https://doi.org/10.1055/s-0040-1709456.

Stern S, Trajtenberg M. Empirical implications of physician authority in pharmaceutical decision making. NBER Working Paper 6851. Cambridge: National Bureau of Economic Research; 1998.

Stucke RS, Kelly JI, Mathis KA, Hill MV, Barth RJ. Association of the use of a mandatory prescription drug monitoring program with prescribing practices for patients undergoing elective surgery. JAMA Surg. 2018;153(12):1105–10. https://doi.org/10.1001/jamasurg.2018.2666.

Talboys R, Mak M, Modi N, Fanous N, Cutts S. Enhanced recovery programme reduces opiate consumption in hip hemiarthroplasty. Eur J Orthop Surg Traumatol. 2016;26(2):177–81. https://doi.org/10.1007/s00590-015-1722-2. Accessed Mar 17, 2020.

Wick EC, Grant MC, Wu CL. Postoperative multimodal analgesia pain management with nonopioid analgesics and techniques: a review. JAMA Surg. 2017;152(7):691–7. Accessed Feb 17, 2020. https://doi.org/10.1001/jamasurg.2017.0898.

Wunsch H, Wijeysundera DN, Passarella MA, Neuman MD. Opioids prescribed after low-risk surgical procedures in the United States, 2004-2012. JAMA. 2016;315(15):1654–7. https://doi.org/10.1001/jama.2016.0130.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions